Cigarette smoking and the risk of incident and fatal melanoma in a large prospective cohort study
- 208 Downloads
Previous studies suggest that smoking may be inversely associated with risk of melanoma. We attempted to replicate this finding using data from the Cancer Prevention Study II (CPS-II) and CPS-II Nutrition cohort, two large prospective cohort studies of cancer mortality and incidence, respectively, with long-term follow-up.
Cox proportional hazards regression analysis was used to examine the association between smoking status and risk of melanoma mortality and incidence among Caucasians in these cohorts. Analyses were adjusted by age, occupation, latitude and educational status.
The incidence rate of melanoma was lower in current than never smokers in both men [hazard ratio (HR): 0.70, 95% confidence interval (CI): (0.48–1.02)] and women [0.50 (0.30–0.83)]; incidence was not lower in former than in never smokers for either sex. The death rate from melanoma was lower in male current than never smokers [0.77 (0.62–0.94)], and in male and female former smokers [0.86 (0.73–1.01)] and [0.83 (0.65–1.06)], respectively. No trends in incidence or mortality were observed in male or female current smokers with years of smoking or cigarettes per day.
This study provides limited support for the hypothesis that smoking reduces melanoma risk. The inconsistent results by smoking status and lack of clear dose–response relationships weaken the evidence for causality.
KeywordsSmoking Melanoma Cohort study
- 4.Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin. doi:10.3322/caac.20073. Accessed 8 Mar 2010
- 23.Burns D, Lee L, Shen L, Gilpin E, et al (1997) Cigarette smoking behavior in the United States. In: Shopland D, Burns D, Garfinkel L, Samet J, (eds), National Cancer Institute Changes in Cigarette-Related Disease Risks and Their Implication for Prevention and Control Smoking and Tobacco Control Monograph No 8. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, NIH Pub No. 97-4213, Bethesda, MD, pp 13–112Google Scholar